Because the number of patients with multiple myeloma is low, the disease is considered ‘ rare’, and Thalidomide Celgene was designated an ‘ orphan medicine ’ (a medicine used in rare diseases) on 20 November 2001.
Et hulgimüeloomiga patsientide arv on väike ja see haigus esineb harva, nimetati Thalidomide Celgene 20. novembril 2001 harvikravimiks.